A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Status:
Completed
Trial end date:
2019-03-19
Target enrollment:
Participant gender:
Summary
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered
once-a-week. Approximately 150 children (males and females) with growth hormone deficiency
(GHD) will be included. All study participants will receive TransCon hGH. This is a global
trial that will be conducted in, but not limited to, the United States, Canada, Australia,
and New Zealand.